IPGaia (IPG) promotes R&D with the aim of acquiring precious intellectual property for the commercialization of new pharmaceuticals, such as composition of matter patents. IPG will select and develop promising research programs and license them out to pharmaceutical companies.
IPG aims to create an ecosystem to assist in the development of new drugs, especially for personalized medicine.
Our mission is to support pharmaceutical companies in the development of a small quantity of a wide variety of drugs to meet the individual medical needs and deliver them quickly, safely, and effectively to as many patients as possible.
| Name of the Company | IPGaia, Inc. | |
|---|---|---|
| Location | 2-5-1 Atago, Minato-ku, Tokyo 105-6236 | |
| Investor | Healthcare New Platform Fund（100％） General Partner; Whiz Partners Inc. | |
| Capital and Capital Reserves | 10 million JPY | |
| Established | October 26th, 2021 | |
| Business Scope |
| |
| Management | President & CEO Chairman | Yasunori Yamaguchi Satoru Iino |
IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) and the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) have entered into a Comprehensive Collaborative Research and Development Agreement (“this agreement”) dated August 7th, 2024. This agreement establishes a formal framework for the incorporation of promising drug target leads from Icahn Mount Sinai into IPG’s drug discovery platform. This agreement enables Icahn Mount Sinai to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of research institutions, including global academia and pharmaceutical companies, …
IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) has entered into a Master Collaborative Research and Development Agreement (“this agreement”) with Tohoku University. This agreement is intended to propose drug discovery seeds handled by Tohoku University Hospital (Sendai, Miyagi Prefecture, Japan; Hospital Director: Hideo Harigae, “Tohoku University Hospital”)※1, regarding IPG platform for efficient generation of high-quality new drugs. This agreement enables IPG to receive proposals for drug discovery seeds handled by Tohoku University Hospital. IPG pursues the joint research program with Tohoku University for identification and development of clinical development candidates with the goal of licensing them to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of …
IPGaia, Inc (IPG) has entered an agreement to collaborate with researchers at Weill Cornell Medicine-Qatar (WCM-Q) to investigate promising targets for the development of new medicines. The Master Collaborative Research and Development Agreement was signed in October 2023 by IPG and Cornell University, based in Ithaca, New York, USA. WCM-Q, based in Doha, is a location of Weill Cornell Medicine in New York, which is part of Cornell University. The Master Agreement establishes a formal framework for the incorporation of promising drug target leads discovered at WCM-Q into IPG’s drug discovery platform. The agreement enables WCM-Q to propose drug targets to IPG for identification and development of lead compounds …
